RNTX
Rein TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RNTX
Rein Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan lung diseases and fibrotic diseases
12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758
--
Rein Therapeutics, Inc., was incorporated under the laws of the State of Delaware on August 6, 2001 and began its main business in 2006. The company is a clinical-stage biopharmaceutical company focused on the development and commercialization of a new class of therapeutic agents called binding peptides. The company's lead product candidate, ALRN-6924, targets the tumor suppressor gene p53 to treat a variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting two primary p53 inhibitory proteins, MDMX and MDM 2. The Company's ongoing ALRN-6924 clinical trials include a Phase 1 trial for the treatment of advanced solid tumors or lymphomas, a Phase 2 trial for the treatment of peripheral T-cell lymphoma, or a Phase 1 trial of PTCL for the treatment of acute myeloid leukemia or AML and advanced myelodysplastic syndrome or MDS, as monotherapy and a Phase 1 trial for the treatment of AML/MDS in combination with cytosine arabinoside or Ara-C.
Company Financials
EPS
RNTX has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.24, beating expectations. The chart below visualizes how RNTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
